Passage Bio (PASG) is trading down at $4.09 (-0.73%), as of the latest quote. It operates in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$37.2M | −$112.9M | −$185.7M | −$138.4M | −$108.4M | −$70.4M | −$49.3M |
| Net income | −$45.6M | −$112.2M | −$185.4M | −$136.1M | −$102.1M | −$64.8M | −$45.5M |
| EPS (diluted) | −$4308.00 | −$58.20 | −$69.60 | −$50.00 | −$37.20 | −$21.04 | −$14.35 |
| Balance sheet | |||||||
| Cash and equivalents | $158.9M | $135.0M | $129.0M | $34.6M | $21.7M | $37.6M | $46.3M |
| Total assets | $178.6M | $328.0M | $355.1M | $243.5M | $150.5M | $102.4M | $62.3M |
| Total liabilities | $4.26M | $23.3M | $36.4M | $42.2M | $39.3M | $41.2M | $43.5M |
| Shareholders' equity | −$56.3M | $304.7M | $318.7M | $201.4M | $111.3M | $61.3M | $18.8M |
| Cash flow | |||||||
| Operating cash flow | −$39.9M | −$80.5M | −$126.9M | −$118.2M | −$78.3M | −$48.0M | −$31.5M |
| Capital expenditure | — | — | — | — | — | $34.0K | — |
| Free cash flow | — | — | — | — | — | −$48.0M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$20.7M | −$14.3M | −$16.5M | −$10.3M | −$8.65M | −$13.8M | −$8.25M | −$8.27M |
| Net income | −$19.3M | −$12.7M | −$15.4M | −$9.38M | −$7.75M | −$13.0M | −$7.56M | −$7.82M |
| EPS (diluted) | −$6.15 | −$3.80 | −$4.87 | −$2.96 | −$2.44 | −$4.08 | −$2.36 | −$2.44 |
| Balance sheet | ||||||||
| Cash and equivalents | $32.3M | $37.6M | $63.4M | $57.6M | $52.8M | $46.3M | $33.3M | $24.2M |
| Total assets | $111.8M | $102.4M | $86.0M | $79.2M | $74.2M | $62.3M | $36.5M | $25.2M |
| Total liabilities | $39.0M | $41.2M | $39.3M | $40.9M | $43.0M | $43.5M | $24.7M | $20.7M |
| Shareholders' equity | $72.7M | $61.3M | $46.7M | $38.3M | $31.1M | $18.8M | $11.8M | $4.46M |
| Cash flow | ||||||||
| Operating cash flow | −$7.45M | −$8.44M | −$13.8M | −$6.33M | −$4.85M | −$6.48M | −$13.0M | −$9.18M |
From Passage Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Passage Bio in our feed yet.